On August 11, CSPC PHARMA rose 3.19% in regular trading, reaching HKD 8.895 per share, with turnover of HKD 302 million.

On the news front, the company announced on August 10 that its monkeypox mRNA vaccine SYS 6037, co-developed with the Chinese Academy of Sciences Institute of Microbiology, has received FDA approval to conduct clinical trials in the United States. SYS 6037 is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, expected to become a competitive product that further enriches the company's mRNA vaccine pipeline.

The gain also extends a rally from the prior session, when the stock advanced 4.43% on deepening AstraZeneca cooperation. On August 5, CSPC received a USD 10 million milestone payment under the strategic R&D collaboration agreement and signed a joint venture contract to build a next-generation biologics production base in Shijiazhuang, with CSPC holding 51% and AstraZeneca 49%. Additionally, the company's interim profit is expected to surge 131.4%-141.3% year-over-year to RMB 5.9-6.2 billion, driven by authorization fee income from the AstraZeneca deal and approximately 10% growth in drug product sales.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)